Validation of the self-test computerised PROTECT Cognitive Test System for detection of dementia and Mild Cognitive Impairment
Corbett, A.; Giske, K. I.; Palmer, A.; Sander-Long, M.; Davis, C.; Stych, K.; O'Leary, M.; Hayman, V.; Bloomfield, A.; Huntley, J.; Aarsland, D.; Castellanos, N.; Griffioen, G.; Nuytten, M.; Fox, C.; Allan, L.; Llewellyn, D.; Ashton, N.; Huber, H.; Hampshire, A.; Cummings, J.; Lamb, S.; Atwell-Thomas, J.; Ballard, C.
Show abstract
Detection and characterisation of dementia and Mild Cognitive Impairment (MCI) is essential for diagnosis and to support recruitment of patients into trials of disease-targeted therapies. Computerised systems offer a means of improving detection in community and primary care settings in a scalable way. This study presents further validation of the self-test PROTECT Cognitive Test System of eight assessments of memory, attention and executive function in 36,941 participants (35,822 healthy, 1046 MCI, 73 dementia). PROTECT shows robust separation of dementia and non-dementia participants (p < 0.001), and good discriminative ability for dementia (Area Under the Curve = 0.966) with 90.90% sensitivity and 87.80% specificity. An optimised detection algorithm robustly identified MCI (P<0.001) and predicted 24-month decline across cognitive domains in both amnestic MCI and non-amnestic MCI phenotypes compared with healthy controls. PROTECT cognitive data also correlated strongly with the plasma biomarkers p-tau217 and Neurofilament Light (n = 46). The system provides a means of improving dementia and MCI detection using self-testing, offering a scalable triage and monitoring tool for clinical pathways and trials.
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
- Evaluation of a speech-based AI system for early detection of Alzheimer’s disease remotely via smartphones 97%
- Relationship of plasma biomarkers to digital cognitive tests in alzheimer's disease 96%
- Plasma p-tau181/Aβ 1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ 1-42 and future cognitive decline 95%
Similar papers in this journal
- Continuous Associations Between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease 96%
- A conformational variant of p53 (U-p53 AZ ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease 95%
- Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment 93%
Similar papers in this journal
- The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: longitudinal findings from the Catch-Cog study cohort 94%
- A metabolite-based machine learning approach to diagnose Alzheimer's-type dementia in blood: Results from the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort 94%
- Association between anticholinergic burden and dementia in UK Biobank 93%
Similar papers in this journal
- Examining a Preclinical Alzheimer’s Cognitive Composite for Telehealth Administration, the tPACC, for Reliability between In-Person and Remote Cognitive Testing with Neuroimaging Biomarkers 96%
- Risk models based on non-cognitive measures may identify presymptomatic Alzheimer’s disease 95%
- FMRI complexity correlates with tau-PET in Late-Onset and Autosomal Dominant Alzheimer's Disease 95%